• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2型糖尿病的基础胰岛素治疗

Basal insulin therapy in type 2 diabetes.

作者信息

Bethel M Angelyn, Feinglos Mark N

机构信息

Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

J Am Board Fam Pract. 2005 May-Jun;18(3):199-204. doi: 10.3122/jabfm.18.3.199.

DOI:10.3122/jabfm.18.3.199
PMID:15879567
Abstract

Patients with type 2 diabetes mellitus are usually treated initially with oral antidiabetic agents, but as the disease progresses, most patients eventually require insulin to maintain glucose control. Optimal insulin therapy should mimic the normal physiologic secretion of insulin and minimize the risk of hypoglycemia. This article discusses the role of insulin therapy in patients with type 2 diabetes, emphasizing long-acting insulin agents designed to approximate physiologic basal insulin secretion and provide control over fasting plasma glucose. Clinical trials of recently developed long-acting insulins are reviewed herein, with emphasis on studies that combined basal insulin with oral agents or with short-acting insulins in a basal-bolus approach. The normal physiologic pattern of insulin secretion by pancreatic beta cells consists of a sustained basal insulin level throughout the day, superimposed after meals by relatively large bursts of insulin that slowly decay over 2 to 3 hours (bolus insulin). Basal support with long-acting insulin is a key component of basal-bolus therapy for patients with diabetes who require insulin with or without the addition of oral agents. Newer long-acting agents such as insulin glargine provide a steadier and more reliable level of basal insulin coverage and may have significant advantages over traditional long-acting insulins as part of a basal-bolus treatment strategy.

摘要

2型糖尿病患者通常最初采用口服抗糖尿病药物治疗,但随着疾病进展,大多数患者最终需要胰岛素来维持血糖控制。最佳胰岛素治疗应模拟胰岛素的正常生理分泌,并将低血糖风险降至最低。本文讨论胰岛素治疗在2型糖尿病患者中的作用,重点介绍旨在近似生理基础胰岛素分泌并控制空腹血糖的长效胰岛素制剂。本文综述了最近开发的长效胰岛素的临床试验,重点是将基础胰岛素与口服药物或短效胰岛素联合采用基础-餐时给药法的研究。胰腺β细胞正常的胰岛素生理分泌模式包括全天持续的基础胰岛素水平,餐后叠加相对大量的胰岛素脉冲,这些脉冲在2至3小时内缓慢衰减(餐时胰岛素)。对于需要胰岛素治疗(无论是否加用口服药物)的糖尿病患者,长效胰岛素提供基础支持是基础-餐时治疗的关键组成部分。新型长效制剂如甘精胰岛素可提供更稳定、更可靠的基础胰岛素覆盖水平,作为基础-餐时治疗策略的一部分,可能比传统长效胰岛素具有显著优势。

相似文献

1
Basal insulin therapy in type 2 diabetes.2型糖尿病的基础胰岛素治疗
J Am Board Fam Pract. 2005 May-Jun;18(3):199-204. doi: 10.3122/jabfm.18.3.199.
2
Basal insulin: physiology, pharmacology, and clinical implications.基础胰岛素:生理学、药理学及临床意义。
Postgrad Med. 2011 Jul;123(4):17-26. doi: 10.3810/pgm.2011.07.2300.
3
Insulin glargine: a systematic review of a long-acting insulin analogue.甘精胰岛素:长效胰岛素类似物的系统评价
Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. doi: 10.1016/s0149-2918(03)80156-x.
4
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.甘精胰岛素与中性鱼精蛋白锌胰岛素治疗2型糖尿病的比较:临床研究综述
J Diabetes Complications. 2007 May-Jun;21(3):196-204. doi: 10.1016/j.jdiacomp.2007.01.001.
5
The past, present, and future of basal insulins.基础胰岛素的过去、现在和未来。
Diabetes Metab Res Rev. 2016 Sep;32(6):478-96. doi: 10.1002/dmrr.2763. Epub 2015 Nov 25.
6
Novel insulins: expanding options in diabetes management.新型胰岛素:拓展糖尿病管理的选择
Am J Med. 2002 Sep;113(4):308-16. doi: 10.1016/s0002-9343(02)01176-2.
7
Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus.甘精胰岛素及其在1型和2型糖尿病治疗中的地位。
Expert Opin Pharmacother. 2006 Jul;7(10):1357-71. doi: 10.1517/14656566.7.10.1357.
8
Innovative insulins--where do analogues fit?创新胰岛素——类似物的定位如何?
Aust Fam Physician. 2006 Dec;35(12):969-73.
9
Insulin glargine: a new basal insulin analogue.甘精胰岛素:一种新型基础胰岛素类似物。
QJM. 2002 Nov;95(11):757-61. doi: 10.1093/qjmed/95.11.757.
10
Insulin glargine.甘精胰岛素
Clin Ther. 2001 Dec;23(12):1938-57; discussion 1923. doi: 10.1016/s0149-2918(01)80148-x.

引用本文的文献

1
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.库欣综合征、肢端肥大症和神经内分泌肿瘤继发糖尿病的实用治疗方法。
Front Endocrinol (Lausanne). 2023 Sep 28;14:1248985. doi: 10.3389/fendo.2023.1248985. eCollection 2023.
2
Clinical Evidence and Practice-Based Guidelines on the Utility of Basal Insulin Combined Oral Therapy (Metformin and Glimepiride) in the Current Era.在当前时代,基础胰岛素联合口服药物治疗(二甲双胍和格列美脲)的临床证据和基于实践的指南。
Curr Diabetes Rev. 2023;19(8):e090123212444. doi: 10.2174/1573399819666230109104300.
3
Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia.
甘精胰岛素与地特胰岛素用于马来西亚初治2型糖尿病(T2DM)患者基础治疗方案的成本效益分析
Clinicoecon Outcomes Res. 2020 Jun 22;12:333-343. doi: 10.2147/CEOR.S244884. eCollection 2020.
4
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?胰岛素/胰高血糖素样肽-1受体激动剂联合疗法治疗2型糖尿病:两种药物是否优于一种?
Clin Diabetes. 2018 Apr;36(2):138-147. doi: 10.2337/cd17-0065.
5
Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.德谷胰岛素/利拉鲁肽(IDegLira)用于治疗2型糖尿病。
Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. doi: 10.1586/17446651.2016.1113129. Epub 2015 Nov 18.
6
Treatment of type 1 and type 2 diabetes mellitus with insulin detemir, a long-acting insulin analog.使用长效胰岛素类似物地特胰岛素治疗1型和2型糖尿病。
Clin Med Insights Endocrinol Diabetes. 2010;3:65-80. doi: 10.4137/CMED.S5330. Epub 2010 Dec 5.
7
Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.长效胰岛素类似物通过胰岛素受体和胰岛素样生长因子-I 受体介导非典型信号事件。
Diabetologia. 2010 Dec;53(12):2667-75. doi: 10.1007/s00125-010-1899-1. Epub 2010 Sep 12.
8
Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes.胰岛素类似物或预混胰岛素类似物与口服药物联合用于治疗2型糖尿病。
MedGenMed. 2007 Apr 16;9(2):12.